The KAZN antibody targets the Kazn protein, also known as Kazrin, a ubiquitously expressed peripheral membrane protein first identified in the early 2000s. Kazn is involved in cell adhesion, migration, and signaling, interacting with cytoskeletal and membrane-associated proteins like ARVCF, p120-catenin, and periplakin. It plays roles in tissue morphogenesis, epidermal differentiation, and wound healing, with isoforms varying in subcellular localization and function.
Kazn’s dysregulation is linked to cancers, skin disorders, and neurodevelopmental conditions. In cancer, Kazn may promote metastasis by modulating cytoskeletal dynamics and epithelial-mesenchymal transition (EMT). In dermatology, it regulates keratinocyte adhesion and differentiation, impacting barrier function.
KAZN antibodies are critical tools for studying these processes, enabling detection of Kazn expression, localization, and interaction partners via techniques like Western blot, immunofluorescence, and co-immunoprecipitation. Commercially available antibodies often target conserved domains (e.g., N-terminal residues) to ensure specificity across isoforms. Recent studies also explore Kazn’s therapeutic potential, with antibodies aiding in validating its role as a biomarker or drug target. Challenges remain in isoform-specific detection due to alternative splicing, necessitating careful antibody validation. Overall, KAZN antibodies contribute to understanding Kazn’s multifaceted roles in health and disease.
(Word count: 199)